AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-07-11 pm EDT			5-day change	1st Jan Change
192.45 ^USD	-1.31%		+1.67%	+8.30%

Jul. 11	AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada	CI
Jul. 11	India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal	RE

Sector Update: Health Care Stocks Softer in Afternoon Trading

Published on 03/25/2024 at 14:01, updated on 03/25/2024 at 14:03

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about AbbVie Inc.

AbbVie Announces Availability of Refresh Advanced OMEGA-3 Lubricant Eye Drops in Canada	Jul. 11	CI
India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal	Jul. 11	RE
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	Jul. 11	RE
INDIA STOCKS-India's equity benchmarks log weekly losses as IT stocks drag	Jul. 11	RE
India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal	Jul. 11	RE
Glenmark Pharma jumps on unit's cancer treatment licensing deal with AbbVie	Jul. 11	RE
INDIA STOCKS-Indian shares inch lower as IT stocks outweigh HUL gains	Jul. 11	RE
India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact	Jul. 10	RE
India's Glenmark Pharma unit, AbbVie sign exclusive licensing pact	Jul. 10	RE
AbbVie and Ichnos Glenmark Innovation Announce Exclusive Global Licensing Agreement for ISB 2001, a First-In-Class CD38xBCMAxCD3 Trispecific Antibody	Jul. 10	CI
AI Mania Masks Trade War Risks	Jul. 10
AbbVie in Immuno-Oncology Licensing Pact with IGI Therapeutics	Jul. 10	DJ
AbbVie Signs Deal to License IGI Therapeutics' ISB 2001 Antibody for Up to $1.93 Billion Plus Royalties	Jul. 10	MT
Glenmark Pharma says Ichnos Glenmark Innovation (IGI), AbbVie announce exclusive global licensing agreement	Jul. 10	RE
Major deals involving U.S. drugmakers and biotechs over the past decade	Jul. 09	RE
Company earnings: key dates for next week	Jul. 09
Organon abandons endometriosis pain drug development after trial failure	Jul. 02	RE
Global markets live: Apple, Google, Boeing, Renault, Macquarie…	Jul. 01
All-Time Highs, All-Time Uncertainty	Jul. 01
Health Care Up as Budget Bill Fears Ease -- Health Care Roundup	Jun. 30	DJ
AbbVie Inc.(NYSE:ABBV) dropped from Russell 1000 Value-Defensive Index	Jun. 30	CI
Sector Update: Health Care Stocks Higher Late Afternoon	Jun. 30	MT
Sector Update: Health Care Stocks Advance Monday Afternoon	Jun. 30	MT
AbbVie to buy Capstan for up to $2.1 billion in immunology push	Jun. 30	RE
AbbVie to buy Capstan for up to $2.1 billion in immunology push	Jun. 30	RE

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.4%), Germany (2.6%), Japan (2%), Canada (1.9%), China (1.6%), France (1.4%), Spain (1%), the United Kingdom (0.9%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and other (9.7%).

Employees

55,000

Sector

Pharmaceuticals

Calendar

Jul. 14 - Détachement de

More about the company